Overview

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Status:
Terminated

Trial end date:
2012-09-05

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with bortezomib may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when given together with gemcitabine and to see how well they work in treating patients with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Northwestern University

Collaborators:

Eli Lilly and Company
Millennium Pharmaceuticals, Inc.

Treatments:

Bortezomib
Gemcitabine